| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
66,921,000 |
| Market
Cap: |
2.83(B) |
| Last
Volume: |
1,212,774 |
Avg
Vol: |
1,001,263 |
| 52
Week Range: |
$38.26 - $89.25 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile QuidelOrtho is engaged in the development, manufacturing and marketing of diagnostic testing solutions. Co. provides diagnostic testing solutions under various brand names, including, among others, the following: Quidel®, QuickVue®, QuickVue+®, Sofia®, Triage®, Solana®, Virena®, MicroVue™, Lyra®, FreshCells™, D3®, FastPoint®, ReadyCells®, Super E-Mix™, InflammaDry®, AdenoPlus®, ELVIRA®, ELVIS® and Thyretain®. Co.'s diagnostic testing solutions are separated into its four product categories: rapid immunoassay, cardiometabolic immunoassay, molecular diagnostic solutions and specialized diagnostic solutions.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hodges Michelle A. |
SVP, General Counsel |
• – – |
2021-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
238 |
238 |
|
- |
|
| Steward Randall J |
Chief Financial Officer |
• – – |
2021-11-18 |
4 |
D |
$144.71 |
$74,236 |
D/D |
(513) |
15,836 |
|
- |
|
| Steward Randall J |
Chief Financial Officer |
• – – |
2021-11-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,033 |
16,349 |
|
- |
|
| Ranalli Tamara A. |
SVP, Molecular Bus. Unit |
• – – |
2021-10-05 |
4 |
D |
$133.79 |
$105,293 |
D/D |
(787) |
13,432 |
|
- |
|
| Ranalli Tamara A. |
SVP, Molecular Bus. Unit |
• – – |
2021-10-05 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
14,219 |
|
- |
|
| Bujarski Robert Joseph |
Chief Operating Officer |
• – – |
2021-09-14 |
4 |
D |
$146.35 |
$22,831 |
D/D |
(156) |
25,324 |
|
- |
|
| Bujarski Robert Joseph |
Chief Operating Officer |
• – – |
2021-09-14 |
4 |
A |
$0.00 |
$0 |
D/D |
313 |
25,480 |
|
- |
|
| Polan Mary Lake Ph D |
Director |
– • – |
2021-09-03 |
4 |
S |
$141.69 |
$873,913 |
D/D |
(6,167) |
19,687 |
|
17% |
|
| Steward Randall J |
Chief Financial Officer |
• – – |
2021-08-24 |
4 |
D |
$121.80 |
$17,661 |
D/D |
(145) |
15,316 |
|
- |
|
| Steward Randall J |
Chief Financial Officer |
• – – |
2021-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
292 |
15,461 |
|
- |
|
| Bryant Douglas C |
President & CEO |
• • – |
2021-08-24 |
4 |
D |
$121.80 |
$88,183 |
D/D |
(724) |
496,543 |
|
- |
|
| Bryant Douglas C |
President & CEO |
• • – |
2021-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,460 |
497,267 |
|
- |
|
| Ranalli Tamara A. |
SVP, Molecular Bus. Unit |
• – – |
2021-08-24 |
4 |
D |
$121.80 |
$9,500 |
D/D |
(78) |
12,219 |
|
- |
|
| Ranalli Tamara A. |
SVP, Molecular Bus. Unit |
• – – |
2021-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
197 |
12,297 |
|
- |
|
| Kroll Werner |
SVP, R&D |
• – – |
2021-07-01 |
4 |
D |
$128.60 |
$65,072 |
D/D |
(506) |
10,723 |
|
- |
|
| Kroll Werner |
SVP, R&D |
• – – |
2021-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
982 |
11,229 |
|
- |
|
| Kroll Werner |
SVP, R&D |
• – – |
2021-05-27 |
4 |
D |
$121.50 |
$273,132 |
D/D |
(2,248) |
10,247 |
|
- |
|
| Kroll Werner |
SVP, R&D |
• – – |
2021-05-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,376 |
12,495 |
|
- |
|
| Widder Kenneth J |
Director |
– • – |
2021-05-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
576 |
16,032 |
|
- |
|
| Polan Mary Lake Ph D |
Director |
– • – |
2021-05-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
485 |
25,854 |
|
- |
|
| Slacik Charles P |
Director |
– • – |
2021-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
734 |
12,199 |
|
- |
|
| Slacik Charles P |
Director |
– • – |
2021-05-13 |
4 |
S |
$113.26 |
$113,258 |
D/D |
(1,000) |
11,465 |
|
-33% |
|
| Wilkins Joseph D Jr. |
Director |
– • – |
2021-05-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
289 |
289 |
|
- |
|
| Buechler Kenneth F |
Director |
– • – |
2021-05-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,040 |
60,864 |
|
- |
|
| Michael Edward L |
Director |
– • – |
2021-05-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,040 |
7,474 |
|
- |
|
799 Records found
|
|
Page 4 of 32 |
|
|
2.54 (6.4%) 
